A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), including crizotinib, are effective treatments in preclinical models and in cancer patients with ALK-translocated cancers. However, their efficacy will ultimately be limited by the development of acquired drug resistance. Here we rep...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2011-09, Vol.71 (18), p.6051-6060
Hauptverfasser:	SASAKI, Takaaki, KOIVUNEN, Jussi, CAPELLETTI, Marzia, SHIMAMURA, Takeshi, ERCAN, Dalia, STUMPFOVA, Magda, YUN XIAO, WEREMOWICZ, Stanislawa, BUTANEY, Mohit, HEON, Stephanie, WILNER, Keith, CHRISTENSEN, James G, OGINO, Atsuko, ECK, Michel J, WONG, Kwok-Kin, LINDEMAN, Neal, GRAY, Nathanael S, RODIG, Scott J, JÄNNE, Pasi A, YANAGITA, Masahiko, NIKIFOROW, Sarah, ZHENG, Wei, LATHAN, Christopher, PAUL MARCOUX, J, JINYAN DU, OKUDA, Katsuhiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Cell Line, Tumor Cell survival Drug resistance Drug Resistance, Neoplasm Epidermal growth factor receptors Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Lung Neoplasms - metabolism Medical sciences Models, Molecular Mutation Non-small cell lung carcinoma Oncogene Proteins, Fusion - biosynthesis Oncogene Proteins, Fusion - genetics Pharmacology. Drug treatments Protein Kinase Inhibitors - pharmacology Protein-tyrosine kinase Pyrazoles - pharmacology Pyridines - pharmacology Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor Protein-Tyrosine Kinases - genetics Receptor Protein-Tyrosine Kinases - metabolism Receptor, Epidermal Growth Factor - metabolism Signal Transduction Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!